Fingolimod Zentiva 0.5 mg kapseli, kova Finska - finščina - Fimea (Suomen lääkevirasto)

fingolimod zentiva 0.5 mg kapseli, kova

zentiva, k.s. - fingolimod hydrochloride - kapseli, kova - 0.5 mg - fingolimodi

Fingolimod Orion 0.5 mg kapseli, kova Finska - finščina - Fimea (Suomen lääkevirasto)

fingolimod orion 0.5 mg kapseli, kova

orion corporation - fingolimod hydrochloride - kapseli, kova - 0.5 mg - fingolimodi

Ticagrelor Krka 60 mg tabletti, kalvopäällysteinen Finska - finščina - Fimea (Suomen lääkevirasto)

ticagrelor krka 60 mg tabletti, kalvopäällysteinen

krka, d.d., novo mesto - ticagrelorum - tabletti, kalvopäällysteinen - 60 mg - tikagrelori

Ticagrelor Krka 90 mg tabletti, kalvopäällysteinen Finska - finščina - Fimea (Suomen lääkevirasto)

ticagrelor krka 90 mg tabletti, kalvopäällysteinen

krka, d.d., novo mesto - ticagrelorum - tabletti, kalvopäällysteinen - 90 mg - tikagrelori

Pemazyre Evropska unija - finščina - EMA (European Medicines Agency)

pemazyre

incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - antineoplastiset aineet - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed  after at least one prior line of systemic therapy.

Byfavo Evropska unija - finščina - EMA (European Medicines Agency)

byfavo

paion deutschland gmbh - remimazolam besilate - tietoinen sedaatio - psyykenlääkkeiden - remimazolam is indicated in adults for procedural sedation. remimazolam 50 mg is indicated in adults for intravenous induction and maintenance of general anaesthesia.

Fingolimod Mylan Evropska unija - finščina - EMA (European Medicines Agency)

fingolimod mylan

mylan ireland limited - fingolimod hydrochloride - multippeliskleroosi, relapsoiva-remittoiva - immunosuppressantit - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 ja 5. 1)orpatients kanssa vaikea ja nopeasti etenevä relapsoiva-remittoiva multippeliskleroosi on määritelty 2 tai enemmän invaliditeettiin sairauden pahenemisvaiheita on yksi vuosi, ja 1 tai enemmän gadolinium parantaa vaurioita aivojen mri tai merkittävä kasvu t2-leesio kuormitus verrattuna aiempaan tuoreeseen magneettikuvaukseen.

Fingolimod Mylan Evropska unija - finščina - EMA (European Medicines Agency)

fingolimod mylan

mylan ireland limited - fingolimod hydrochloride - multippeliskleroosi, relapsoiva-remittoiva - immunosuppressantit - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 ja 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Agil 100 EC Finska - finščina - Adama

agil 100 ec

adama - propakvitsafoppi 100 g/l - rikkakasvien torjunta

Cloud Finska - finščina - Adama

cloud

adama - kvinmerakki / kvinmerak 125 g/l + metatsaklori / metazaklor 375 g/l - rikkakasvien torjunta